In a report published Monday, analysts at Avondale upgraded their rating on the shares of BioTelemetry, Inc. (BEAT) to ‘Market Perform’. The target price has been set to $15.00 from $8.00. BioTelemetry’s shares closed at $8.11 Friday. Avondale’s target price suggests a potential upside of about 72% from the name’s current price. BioTelemetry, Inc. (BEAT) […]
View the full post at: Front Runners: BioTelemetry (BEAT), Outerwall Inc. (OUTR), Amicus Therapeutics, Inc. (FOLD), Five Prime Therapeutics (FPRX), Apple (AAPL)